Top Companies in Global CAR T-Cell Therapy Market
This report lists the top Global CAR T-Cell Therapy companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Global CAR T-Cell Therapy industry.
-
Novartis
-
Bristol-Myers Squibb
-
Johnson & Johnson
-
Sorrento Therapeutics
-
Gilead Sciences
*Disclaimer: Top companies sorted in no particular order
Global CAR T-Cell Therapy Market Concentration
Global CAR T-Cell Therapy Company List
Novartis AG
Bristol-Myers Squibb Company
Gilead Sciences, Inc. (Kite Pharma)
Johnson & Johnson
Eli Lilly and Company
Sorrento Therapeutics, Inc.
ACROBiosystems
Celyad Oncology
Sangamo Therapeutics, Inc.
Servier Laboratories
Noile-Immune Biotech, Inc.
Miltenyi Biotec
Specific to Global CAR T-Cell Therapy Market
Competitive Landscape Report Includes
Company Profiles (includes Global Level Overview, Market Level Overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and Analysis of Recent Developments). Key Strategic Moves, Market Share Analysis, Company Landscape, and List of Companies.
Global CAR T-Cell Therapy Market Companies Summary
The CAR T-cell therapy industry has been significantly impacted by the COVID-19 pandemic, leading to a decrease in patients undergoing therapy due to the high risk of poor outcomes. However, with the introduction of vaccines and easing of lockdown restrictions, research and development activities have resumed, and patient visits have increased, indicating potential growth in the market. The industry's growth can be attributed to the increasing burden of cancer and the rise in research and development to develop CAR T-cell therapy. The anticipated increase in cancer cases is expected to drive the demand for this therapy. Additionally, increasing research and development activities are contributing to market growth. Several firms in the CAR T-cell therapy market have reported significant developments, driving the demand for CAR T-cell therapies and contributing to market growth. However, the high cost of developing CAR T-cell therapy is a major factor hindering market growth. The market is moderately competitive with several global and international players. These key players are adopting various growth strategies, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions, to enhance their market presence.
Explore MoreGlobal CAR T-Cell Therapy Companies - Table of Contents
-
1. COMPETITIVE LANDSCAPE
-
1.1 Company Profiles
-
1.1.1 Novartis AG
-
1.1.2 Bristol-Myers Squibb Company
-
1.1.3 Gilead Sciences, Inc. (Kite Pharma)
-
1.1.4 Johnson & Johnson
-
1.1.5 Eli Lilly and Company
-
1.1.6 Sorrento Therapeutics, Inc.
-
1.1.7 ACROBiosystems
-
1.1.8 Celyad Oncology
-
1.1.9 Sangamo Therapeutics, Inc.
-
1.1.10 Servier Laboratories
-
1.1.11 Noile-Immune Biotech, Inc.
-
1.1.12 Miltenyi Biotec
-
- *List Not Exhaustive
-
Global CAR T-Cell Therapy Companies FAQs
Who are the key players in Global CAR T-Cell Therapy Market?
Novartis AG, Bristol-Myers Squibb Company, Johnson & Johnson, Sorrento Therapeutics, Inc. and Gilead Sciences, Inc. (Kite Pharma) are the major companies operating in the Global CAR T-Cell Therapy Market.